Summit Global Investments Sells 3,327 Shares of United Therapeutics Corporation $UTHR

Summit Global Investments cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 18.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 15,006 shares of the biotechnology company’s stock after selling 3,327 shares during the quarter. Summit Global Investments’ holdings in United Therapeutics were worth $6,291,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics in the second quarter worth approximately $29,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. boosted its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB increased its position in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the period. Finally, Geneos Wealth Management Inc. raised its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on UTHR. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a report on Wednesday, October 29th. Royal Bank Of Canada increased their target price on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. UBS Group lifted their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Wells Fargo & Company boosted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 1,000 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the sale, the director directly owned 4,190 shares of the company’s stock, valued at $2,136,900. This trade represents a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $469.89, for a total value of $3,900,087.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $17,283,024.09. This trade represents a 18.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 566,864 shares of company stock worth $269,514,607 in the last quarter. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Up 0.1%

United Therapeutics stock opened at $467.70 on Friday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99. The company’s 50 day moving average price is $487.37 and its two-hundred day moving average price is $418.94. The stock has a market cap of $20.14 billion, a P/E ratio of 17.72, a P/E/G ratio of 2.50 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same period last year, the firm posted $6.39 EPS. The business’s revenue was up 6.8% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.